Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating

Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock.

Keep Reading →